Ignite Creation Date:
2024-10-25 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06518538
Status:
WITHDRAWN
Last Update Posted:
None
First Post:
2024-07-18
Brief Title:
Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Single Center Open-Label Trial to Evaluate Efficacy and Safety of Devimistat in Combination With Modified FOLFIRINOX mFFX in 2nd Line Patients With Metastatic Adenocarcinoma of the Pancreas
Status:
WITHDRAWN
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
due to study redesign
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Open label randomized phase II study to evaluate efficacy and safety of CPI-613 mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None